Necitumumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Necitumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetEGFR
Clinical data
Trade namesPortrazza
AHFS/Drugs.comMultum Consumer Information
License data
Routes of
administration
Intravenous infusion
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life~14 days
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6436H9958N1702O2020S42
Molar mass144.84 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-small-cell lung carcinoma.[4][5]

References[edit]